Stock Comparison

NVDA vs RXRX

NVIDIA Corp vs Recursion Pharmaceuticals Inc

The Verdict

RXRX takes this one.

NVDA

NVIDIA Corp

5.3

out of 10

Proceed with Caution

Winner

RXRX

Recursion Pharmaceuticals Inc

7.0

out of 10

Solid Pick

Head-to-Head

$4.4T

Market Cap

$1.9B

38.5

P/E Ratio

-2.3

55.6%

Profit Margin

-863.4%

97.4%

Return on Equity

-64.0%

0.0

Debt-to-Equity

0.0

Moderate

Overall Risk

Aggressive

5.3

DVR Score

7.0

The Deep Dive

NVDA5.3/10

NVIDIA maintains its undisputed leadership in AI and accelerated computing, anchored by its critical CUDA platform and constant hardware innovation, exemplified by the Vera Rubin platform and $1 trillion in projected orders. Its strategic vision for pervasive AI, robotics, and the Omniverse targets vast, expanding markets, demonstrating exceptional competitive advantages and robust financial perfo...

Full NVDA Analysis

RXRX7.0/10

Recursion Pharmaceuticals (RXRX) continues to exhibit significant long-term disruptive potential with its AI/ML Biofoundry and established partnerships, validated by a strong Q4 2025 revenue beat and positive early-stage clinical data. However, financial health remains a primary concern, characterized by deep unprofitability (-863.37% net margin) and high projected cash burn. The recent news of fo...

Full RXRX Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.